211 related articles for article (PubMed ID: 37182666)
1. Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy.
Kumari S; Gupta R; Ambasta RK; Kumar P
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188913. PubMed ID: 37182666
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
3. Targeting Glioblastoma Tumor Microenvironment.
Butler M; Prasad S; Srivastava SK
Adv Exp Med Biol; 2020; 1296():1-9. PubMed ID: 34185283
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted therapy: A new avenue in glioblastoma treatment.
El Atat O; Naser R; Abdelkhalek M; Habib RA; El Sibai M
Oncol Lett; 2023 Feb; 25(2):46. PubMed ID: 36644133
[TBL] [Abstract][Full Text] [Related]
5. Emerging trends in post-translational modification: Shedding light on Glioblastoma multiforme.
Kumari S; Gupta R; Ambasta RK; Kumar P
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188999. PubMed ID: 37858622
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma multiforme: novel therapeutic targets.
Muir M; Gopakumar S; Traylor J; Lee S; Rao G
Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications.
Yang L; Lin C; Wang L; Guo H; Wang X
Exp Cell Res; 2012 Nov; 318(19):2417-26. PubMed ID: 22906859
[TBL] [Abstract][Full Text] [Related]
8. Clinical Theranostics Trademark of Exosome in Glioblastoma Metastasis.
Nag S; Bhattacharya B; Dutta S; Mandal D; Mukherjee S; Anand K; Eswaramoorthy R; Thorat N; Jha SK; Gorai S
ACS Biomater Sci Eng; 2023 Sep; 9(9):5205-5221. PubMed ID: 37578350
[TBL] [Abstract][Full Text] [Related]
9. Non-Tumor Cells within the Tumor Microenvironment-The "Eminence Grise" of the Glioblastoma Pathogenesis and Potential Targets for Therapy.
Bugakova AS; Chudakova DA; Myzina MS; Yanysheva EP; Ozerskaya IV; Soboleva AV; Baklaushev VP; Yusubalieva GM
Cells; 2024 May; 13(10):. PubMed ID: 38786032
[TBL] [Abstract][Full Text] [Related]
10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
11. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.
Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y
Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735
[TBL] [Abstract][Full Text] [Related]
12. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
[TBL] [Abstract][Full Text] [Related]
13. Organoid models of glioblastoma: advances, applications and challenges.
Zhang C; Jin M; Zhao J; Chen J; Jin W
Am J Cancer Res; 2020; 10(8):2242-2257. PubMed ID: 32905502
[TBL] [Abstract][Full Text] [Related]
14. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment.
Kalkan R
Crit Rev Eukaryot Gene Expr; 2015; 25(4):363-9. PubMed ID: 26559096
[TBL] [Abstract][Full Text] [Related]
16. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer.
Urbaniak A; Reed MR; Heflin B; Gaydos J; Piña-Oviedo S; Jędrzejczyk M; Klejborowska G; Stępczyńska N; Chambers TC; Tackett AJ; Rodriguez A; Huczyński A; Eoff RL; MacNicol AM
Biomed Pharmacother; 2022 Sep; 153():113440. PubMed ID: 36076555
[TBL] [Abstract][Full Text] [Related]
17. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
18. Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment.
Khodadadi H; Salles ÉL; Alptekin A; Mehrabian D; Rutkowski M; Arbab AS; Yeudall WA; Yu JC; Morgan JC; Hess DC; Vaibhav K; Dhandapani KM; Baban B
Cannabis Cannabinoid Res; 2023 Oct; 8(5):824-834. PubMed ID: 34918964
[No Abstract] [Full Text] [Related]
19. Identification of Necroptosis-related Molecular Subtypes and Construction of Necroptosis-related Gene Signature for Glioblastoma Multiforme.
Li Z; Jin Y; Que T; Zhang XA; Yi G; Zheng H; Yuan X; Wang X; Xu H; Nan J; Chen C; Wu Y; Huang G
Curr Med Chem; 2023 Aug; ():. PubMed ID: 37539935
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Role of Glutamate Signaling in Glioblastoma Multiforme: Current Therapeutic Modalities and Future Directions.
Mollazadeh H; Mohtashami E; Mousavi SH; Soukhtanloo M; Vahedi MM; Hosseini A; Afshari AR; Sahebkar A
Curr Pharm Des; 2020; 26(37):4777-4788. PubMed ID: 32493186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
